Rates and risk factors for discontinuation of rifampicin
| Autor: | S V, Cook, P I, Fujiwara, T R, Frieden |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male Adolescent White People Risk Factors Confidence Intervals Odds Ratio Humans Child Antibiotics Antitubercular Tuberculosis Pulmonary Aged Retrospective Studies Analysis of Variance Incidence Hispanic or Latino Middle Aged Drug Utilization Substance Withdrawal Syndrome Logistic Models Case-Control Studies Multivariate Analysis Patient Compliance Female New York City Rifampin |
| Zdroj: | The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 4(2) |
| ISSN: | 1027-3719 |
| Popis: | All patients with culture-confirmed, rifampin-susceptible Mycobacterium tuberculosis diagnosed during a 20-month period in New York City, who were started on a rifampin-containing regimen and receivedor =60 days of treatment.To identify rates of and reasons for rifampin discontinuation.Retrospective case-control study using surveillance data and medical record reviews. Discontinuation due to thrombocytopenia, creatinine2.0 mg/dl, bilirubin2.0 mg/dl or severe reactions (generalized rash, persistent drug fever, or severe interference with methadone metabolism) were defined as appropriate for discontinuation of rifampin. All other reactions were classified as inappropriate.Of 3,520 patients, rifampin was discontinued in 68 (1.9%); of these, 57% had rifampin discontinued unnecessarily. Treatment by an inexperienced provider (adjusted odds ratio [ORadj] 4.0; 95% confidence interval [CI] 1.9-8.5), race (ORadj 3.1; 95%CI 1.4-6.9), history of previous treatment (ORadj 4.8; 95%CI 1.9-12.5), and history of methadone drug treatment (ORadj 12.6; 95%CI 5.3-29.9) were all associated with inappropriate rifampin discontinuation.True intolerance was rare, even among those patients infected with the human immunodeficiency virus. Most patients with minor reactions can successfully complete treatment with rifampin, particularly if managed by a physician experienced in the treatment of tuberculosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|